Yuichi Miyagawa, Ryota Akabane, Atsushi Sakatani, Mizuki Ogawa, Masayoshi Nagakawa, Hirosumi Miyakawa, Naoyuki Takemura
Research in veterinary science 2020 DecRenal proteinuria is associated with promoted renal dysfunction and a shorter survival period in dogs with chronic kidney disease (CKD). Renin angiotensin- aldosterone system inhibitors are primarily used to treat renal proteinuria. In this retrospective, open-label study, we aimed to evaluate the anti-proteinuric and anti-hypertensive effects of telmisartan (angiotensin II receptor blocker) in dogs with proteinuric CKD. A total of 28 dogs with proteinuric CKD were included in the study, all dogs received telmisartan 1 mg/kg q24h, PO. The urine protein-to-creatinine ratio (UPC), urine albumin-to-creatinine ratio (UAC) and systolic blood pressure (SBP) decreased significantly after telmisartan administration (P < 0.05). The median rate of change in UPC, UAC and SBP at Day 120 were - 65.1%, -75.9% and - 9.7%. Ten dogs (36.7%) achieved UPC < 1.0 at Day 120, of which six dogs had UPC < 0.5. A reduction of UPC to ≥50% was achieved in 10 dogs (36%) at Day 45 and 17 dogs (61%) at Day 120. Seventeen dogs (61%) had hypertension at baseline, of which 10 dogs (59%) had SBP < 160 mmHg at Day 120. Two-way repeated measures analysis of variance did not attribute the observed changes in SBP, UPC or UAC to feeding with a renal diet. In conclusion, telmisartan therapy provides anti-proteinuric and anti-hypertensive effects in dogs with proteinuric CKD. Copyright © 2020 Elsevier Ltd. All rights reserved.
Yuichi Miyagawa, Ryota Akabane, Atsushi Sakatani, Mizuki Ogawa, Masayoshi Nagakawa, Hirosumi Miyakawa, Naoyuki Takemura. Effects of telmisartan on proteinuria and systolic blood pressure in dogs with chronic kidney disease. Research in veterinary science. 2020 Dec;133:150-156
PMID: 32992126
View Full Text